section name header

Evidence summaries

S-Adenosyl-L-Methionine (Same)for Alcoholic Liver Diseases

S-adenosyl-L-methionine may not have any effect on the outcome of alcoholic liver disease, but the evidence is inconclusive. Level of evidence: "C"

A Cochrane review [Abstract] 1 [withdrawn from publication] included 9 studies with a total of 434 subjects. There was no significant effect of SAMe on all-cause mortality (relative risks (RR) 0.62, 95% CI 0.30 to 1.26), liver-related mortality (RR 0.68, 95% CI 0.31 to 1.48), all-cause mortality or liver transplantation (RR 0.55; 95% CI 0.27 to 1.09), or complications (RR 1.35, 95% CI 0.84 to 2.16), but the analysis is based mostly on one trial only (n=123).

Comment: The quality of evidence is downgraded by imprecise results (few patients and wide confidence intervals) and by inconsistency (variability in results across studies).

    References

    • Rambaldi A, Gluud C. WITHDRAWN: S-adenosyl-L-methionine for alcoholic liver diseases. Cochrane Database Syst Rev 2015;(11):CD002235. [PubMed]

Primary/Secondary Keywords